SCHEMBL374733

SCHEMBL374733

[CH]=C/C=C\CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20053 1.00
SCHEMBL20052 1.00
SCHEMBL816679 0.87 TRPA1 (0.43)
SCHEMBL232586 0.87
SCHEMBL815297 0.87 TRPA1 (0.43)
SCHEMBL817001 0.87 TRPA1 (0.43)
SCHEMBL817000 0.87 TRPA1 (0.43)
SCHEMBL814955 0.87 TRPA1 (0.43)
SCHEMBL4817022 0.87 TRPA1 (0.43)
SCHEMBL816680 0.87 TRPA1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734209-B2 MACROCYCLIC LACTONES HAVING ANTI-CANCER ACTIVITY AND VACUOLAR ATPASE INHIBITORY ACTIVITY BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM 2004-05-11 US claimed
US-20040063778-A1 Synthetic salicylihalamides, apicularens and derivatives thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-04-01 US claimed
US-6617348-B1 Treating or preventing osteoporosis UT SOUTHWESTERN MEDICAL CENTER 2003-09-09 US claimed
EP-1307439-A2 SYNTHETIC SALICYLIHALAMIDES, APICULARENS AND DERIVATIVES THEREOF Board of Regents, The University of Texas System (US) 2003-05-07 EP claimed
WO-2002012223-A2 SYNTHETIC SALICYLIHALAMIDES, APICULARENS AND DERIVATIVES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-02-14 WO claimed
US-12043639-B2 Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells MOLECULAR TRANSFER, INC. (US) 2024-07-23 US disclosed
CN-118355022-A Nucleoside analogues for the treatment of parasitic infections 安特卫普大学 2024-07-16 CN disclosed
EP-4387949-A1 PROCESS FOR THE PRODUCTION OF LEVULINIC ACID AND DERIVATIVES THEREOF Universiteit Antwerpen (BE) 2024-06-26 EP disclosed
EP-4384508-A2 LIPIDS FOR NUCLEIC ACID DELIVERY Life Technologies Corporation (US) 2024-06-19 EP disclosed
CN-118076576-A Process for the production of levulinic acid and derivatives thereof 安特卫普大学 2024-05-24 CN disclosed
CN-114206864-B Quinazoline-2, 4-dione derivatives as PARP inhibitors 苏州四体康宸医药科技有限公司 2024-05-24 CN disclosed
WO-2024031051-A1 LIPIDS FOR NUCLEIC ACID DELIVERY Life Technologies Corporation (US) 2024-02-08 WO disclosed
US-5691372-A Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-11-25 US disclosed
WO-1997027180-A1 ASPARTYL PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-07-31 WO disclosed
WO-1997012855-A1 BUTYRATE PRODRUGS OF LACTIC ACID VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-04-10 WO disclosed
CN-1146201-A Sulphonamide derivatives as aspartyl protease inhibitors VERTEX PHARMA (US) 1997-03-26 CN disclosed
EP-0749421-A1 SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 1996-12-27 EP disclosed
WO-1996033187-A1 OXYGENATED-HETEROCYCLE CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1996-10-24 WO disclosed
WO-1996033184-A1 THF-CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1996-10-24 WO disclosed
WO-1995024385-A1 SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 1995-09-14 WO disclosed